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Introduction
Focal segmental glomerulosclerosis (FSGS) is one of the most 
common causes of proteinuric kidney disease that eventually 
progresses to the end-stage renal failure. Molecular stud-
ies revealed a central role of glomerular podocyte damage in 
the development of FSGS.1,2 A growing number of proteins, 
expressed by podocytes, contributing to the structure and 
function of the slit diaphragm (eg, nephrin (NPHS1), podocin 
(NPHS1)), cytoskeleton (eg, alpha-actinin 4 (ACTN4)) and/
or podocyte signaling (eg, inverted formin 2 (INF2), Wilms 
tumor protein 1 (WT1), TRPC6 (TRPC6), PLCE1 (phospho-
lipase C epsilon 1, PLCE1)), cause FSGS when mutated.1,2
The lack of CD2-associated protein (CD2AP) in mice 
results in severe congenital nephrotic syndrome: Cd2ap−/− mice 
die of massive proteinuria shortly after birth, and Cd2ap+/− 
mice present glomerular disease at nine months with a kidney 
histology that mimics human FSGS.3 The renal phenotype of 
Cd2ap−/−-deficient animals is rescued by podocyte transfec-
tion with CD2AP.4
In spite of the clear association of CD2AP defects with a 
glomerular pathology reminiscent of FSGS in mouse models, 
little is known about CD2AP in humans. Kim et al described 
one heterozygous nucleotide variant resulting in an aberrant 
CD2AP splicing in two patients with idiopathic FSGS.3 The 
protein product of this variant message would lack .80% of 
the CD2AP protein. Löwik et al described a patient affected 
by early onset nephrotic syndrome with a CD2AP homozygous 
mutation (p.R612X), resulting in a premature stop codon yield-
ing a slightly truncated protein (by only 4%).5 The boy was born 
of consanguineous parents of Mediterranean ancestry, each of 
whom was unaffected and carried the mutation in heterozygous 
state, indicating that heterozygosity for this mutation does not 
result in kidney disease. Three additional heterozygous muta-
tions in CD2AP (p.K301M, p.T374A, p.delGlu525) were found 
in three unrelated Italian patients with idiopathic FSGS.6 Two 
recently identified mutations in CD2AP (IVS13-137G . A, 
IVS7–135G . A) are likely FSGS-causing DNA variants.7
Overall, the mutations described so far remain unique, so 
it is still uncertain whether CD2AP mutations have a real clin-
ical impact in causing an inherited form of FSGS in man. In 
this study, we report a German patient with steroid- resistant 
FSGS and identified a heterozygous CD2AP mutation 
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(p.T374A), which was previously identified in an unrelated 
Italian patient with FSGS.6 Our results show that a unique 
heterozygous CD2AP mutation (p.T374A) occurs indepen-
dently in two different patients/families with FSGS, support-
ing the idea that p.T374A is likely a pathogenic mutation and 
the overall concept that CD2AP-associated nephropathy is an 
autosomal dominant form of FSGS in man. The patient has 
given consent for publication of this report.
case Presentation
The 32-year-old patient presented with a nephrotic syndrome 
(proteinuria .3.5 g/day) at the age of 28. He had swellings 
around his eyes, swollen ankles and feet, and foamy urine. 
There was no remarkably deteriorated kidney function at the 
point of initial presentation (serum creatinine, 110 µmol/L; 
estimated glomerular filtration rate (eGFR) 77.7 mL/minute). 
He is the child of nonconsanguineous German parents. He 
successfully completed 10 years of middle school education 
and a three-year apprenticeship (Berufsschule) as a carpen-
ter. The patient reported that his mother and his only brother 
also have a kidney disease. Otherwise, his family history is 
not remarkable. Blood samples or clinical reports of his rela-
tives are not available because he lost all contacts with them. 
Never theless, the family history is consistent with an auto-
somal dominant pattern of the disease.
Kidney biopsy showed the histopathological findings of 
FSGS (Figs. 1A and 1B; Supplementary Fig. 1). Therapy with 
steroids was performed over a six-month period with a tran-
sient clinical benefit. Concomitantly, the patient received anti-
proteinuric therapy with an angiotensin-converting enzyme 
inhibitor (ramipril, 10 mg/day). Because of the relapse of protei-
nuria (.3.5 g/day), he received a repeated kidney biopsy, which 
also confirmed FSGS. Neurological examination showed a 
remarkable cognitive decline within five years of his initial 
presentation. Interestingly, one physician initially suspected an 
alcoholic etiology of the cognitive impairment in our patient, 
but a more detailed examination of the patient’s behavior and 
social environment by his local nephrologists, neurologist, and 
assisted living staff revealed this etiology to be rather unlikely. 
After five years of initial presentation, the patient’s mini–men-
tal state examination score was 21 out of 30.
Mutational analysis revealed a heterozygote p.T374A, 
c.1120 A . G mutation in CD2AP (Fig. 2A). The mutation 
is located in the coding region of the proline-rich domain of 
CD2AP (Fig. 2B). The same mutation was previously identi-
fied in a patient with histology-proven FSGS, who developed 
nephrotic syndrome at early childhood similar to other patients 
with CD2AP-associated nephropathy (Table 1).6 We did not 
find mutations in other known FSGS genes causing auto-
somal dominant FSGS, including TRPC6, ACTN4, and WT1 
(NPHS4; exons 8 und 9). In INF2, we found a small deletion 
(6 bp) in exon 8, which results in a deletion of two amino acids 
(p.PPL . L (427–429)). Small deletions in this gene region 
are reported in NHLBI Exome Sequencing Project Exome 
Figure 1. Histopathological findings of a kidney biopsy of our patient. 
(A) electron microscopy showing peripheral glomerular loop with 
widespread podocyte foot processes effacement (arrows). Mesangium, 
endothelium, and glomerular basement membrane are normal. scale 
bar = 2 µm. (b) light microscopy showing a glomerulus with segmental 
glomerular sclerosis. this glomerulus shows the loss of capillary 
lumen and the adhesion of sclerotic lesions to the Bowman’s capsule. 
no endothelial hypercellularity and no activated podocytes. scale 
bar = 50 µm.
Variant Server TMP_ESP_14_105173884, but not in Human 
Genome Mutation Database (HGMD Pro; www.hgmd.
cf.ac.uk) or Ensembl (www.ensembl.org). The significance of 
this deletion is unknown but is not predicted to be pathogenic 
by SIFT8 and MutationTaster9 predictions algorithms.
Subsequently, a therapy with steroid (prednisolone, 5 mg/
day) and low-intermediate doses of cyclosporine A (CsA; 
trough levels, 15–30 µg/L) was performed. This therapy led to 
a persistent reduction of proteinuria. Serum creatinine levels 
and eGFR reached a plateau and did not decline during this 
treatment (Fig. 3).
Methods
The patient was entered into genetic testing after having given 
written informed consent. DNA was isolated from peripheral 
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blood leukocytes, using a commercially available DNA isolation 
kit: EZ1 DNA Blood 200-µL Kit, QIAGEN EZ1 DNA Blood 
card, as suggested by Qiagen Supplementary Protocol. The ampli-
fication of TRPC6 (GenBank accession number, Ensembl Tran-
script ID ENST00000344327), ACTN4 (ENST00000252699), 
WT1 (ENST00000332351), CD2AP (ENST00000359314), and 
INF2 (ENST00000392634) exons was performed by the poly-
merase chain reaction (PCR). Primer data and PCR protocols 
are available on request. The 5′-UTR of CD2AP was also ana-
lyzed. The PCR products were analyzed with ABI 3100-Avant 
Genetic Analyzer (Applied Biosystems) by BigDye terminator 
reaction according to the supplier’s instructions (ABI Prism 
BigDye Terminator Cycle Sequencing Ready Reaction Kits 
Version 1.1; Applied Biosystems). The sequences were analyzed 
by Sequence Pilot program with the SeqPatient V.3.5.2 mod-
ule ( JSI medical system GmbH). Paraffin sections from kidney 
biopsy were analyzed by routine renal biopsy examination.
conclusion
Mutations in CD2-associated protein gene (CD2AP) have 
been identified in patients with FSGS (Table 1). However, 
reports of CD2AP mutations and the associated phenotype(s) 
remain scarce. All previous reports describe the sequence 
variations/mutations of CD2AP in individuals of unre-
lated families. However, there are no reports on unrelated 
patients who have any of these known mutations and FSGS. 
table 1. described cases of focal segmental glomerulosclerosis with mutations in CD2AP.
PAtiEnt id SEx nuClEotidE ChAnGE; AA ChAnGE AGE At onSEt (YEARS) RESiStAnCE to StERoidS REF.
1, 2# F, M# c.1120 a . g; p.t374a het 2, 28# Resistant# gigante6
3 F c.904 a . t; p.K301M het 23 Resistant gigante6
4 M c.1573delaga; p.delglu525 het 2 Resistant gigante6
5 M c.1834 C . a; R612X hom 1 Resistant löwik5
6 M c.1488 g . a; p.M496i het 3.5 Resistant löwik10
7 M iVs13-137g . a het 8 Resistant Feng7
8 M iVs7-135g . a het 4.7 Resistant Feng7
note: #our index patient. 
Abbreviations: M, male; F, female; aa, amino acid; het, heterozygous; hom, homozygous.
A
B
Exon 12 (c.1120)
A A A AA/G GT TC CC
A A
A A
A AA/G
T/C
G
Direction: forward
Direction: reverse
p.K301M
SH3 SH3 SH3 PRD CC 639
p.T374A p.del525Glu p.R612X
G G G
T
T T T T
TC C
C
C
Figure 2. (A) DNA-sequencing fluorograms demonstrating heterozygosity for c.1120 A . g in CD2AP in our patient. (b) schematic representation of the 
Cd2ap protein. Mutation positions are indicated by arrows. sh3, sh3 domains; pRd, proline-rich domain. Coiled-coil domain located at the C terminus.
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In addition, there is no proven effective therapy for CD2AP-
associated nephropathy.
Ours is the first case of CD2AP-associated nephropathy 
associated with a sequence variation (p.T374A, c.1120 A . G), 
which was previously reported for another, unrelated patient 
with this disorder.6 Of note in the study by Gigante et al, 
the patient presented overt proteinuria with nephrotic syn-
drome at pediatric age. As known for other cases of CD2AP-
 associated nephropathy,5,6,10 his nephropathy showed a high 
degree of resistance to steroids, but definitive data on pro-
gression to end-stage renal failure are not available. Clinical 
data of his family members were not available to determine 
cosegration of this mutation with the phenotype.6 In contrast 
to the patient in Gigante et al, our patient developed overt 
proteinuria at the adult age (Table 1). The kidney biopsies in 
both patients showed FSGS. In addition, proteinuria in both 
patients was resistant to steroids. Accordingly, the p.T374A 
mutation is now the first sequence variation of CD2AP found 
in two unrelated patients/families with FSGS, which con-
solidates the idea that this mutation is a likely pathogenic 
mutation causing FSGS in humans.11 Moreover, our findings 
support the concept that haploinsufficiency in CD2AP can 
cause FSGS in humans. In the 1000 genomes browser, the 
p.T374A is reported in ,0.5% of population, but clinical data 
are missing. The mutation (c.1120 A . G) produces an A-to-G 
nucleotide change in exon 12, resulting in the substitution 
of threonine 374 with alanine (p.T374A).6 It is a missense 
mutation localized in the proline-rich domain containing 
three core PXKP motifs that act as binding sites for the SH3 
domain of other podocyte proteins. Multiple alignments of 
amino acid sequences showed high conservation of Thr-374 
across animal species.6 Together, the present data support the 
view that CD2AP p.T374A is likely a FSGS-causing mutation 
in humans.
Our patient is the first patient with CD2AP- associated 
nephropathy treated with low-dose steroids and low-
 intermediate doses of CsA. This treatment reduced his pro-
teinuria rate by ∼70%. Although definitive data on the 
progression to advanced stage renal failure are not available, 
this reduction in proteinuria is remarkable. We believe that 
our report may be useful for nephrologists who treat patients 
with CD2AP- associated nephropathy. Our data indicate that 
CsA is a therapeutic option for patients with CD2AP-associ-
ated nephropathy. On the other hand, the CsA response may 
explain why only very few patients with CD2AP-associated 
nephropathy have been identified so far.12 Genetic testing is 
usually performed in patients with kidney disease who are 
distinct from these clinical features, namely patients with 
therapy-resistant FSGS and a positive family history. Interest-
ingly, MYO1E- and PLCE1-associated nephropathies are the 
only hereditary kidney diseases known to respond to treat-
ment with CsA.13,14 The mechanism is unknown, but there is 
evidence that CsA may exhibit protective effects in podocytes 
by blocking synaptopodin dephosphorylation15 and the loss 
of CD2AP.16
Our patient displayed mild dementia in young adulthood, 
a phenotypic characteristic not previously associated with 
CD2AP-associated FSGS. It is not clear whether this feature 
represents a typical characteristic of those patients in adult-
hood or not. The majority of patients with CD2AP-associated 
nephropathy had onset of renal symptoms before five years of 
age (Table 1), and there is no information about their intel-
lectual capabilities at an adult age. It is important to know 
whether cognitive impairment will also develop in patients 
with childhood-onset, CD2AP-associated nephropathy later in 
life. Of note, common variants at CD2AP are associated with 
Alzheimer’s disease,17 which may indicate that CD2AP muta-
tions can be associated with or cause cognitive impairment. 
Nevertheless, we cannot rule out with absolute certainty that 
other factors could have caused or contributed to our patient’s 
mild dementia.
In conclusion, our findings expand the clinical spec-
trum of CD2AP-associated disorders. The results highlight 
the impact of CD2AP mutations also in adulthood protei-
nuric disease. From the clinical point of view, the genetic 
testing of CD2AP should be considered in adulthood steroid-
resistant nephrotic syndrome/FSGS. Our case shows that 
cyclosporin A is a treatment option for FSGS in p.T374A 
CD2AP-associated nephropathy.
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Figure 3. treatment of our patient with Csa. (A) decline of proteinuria 
measured in grams per day or as protein/creatinine ratio (g/g) in urine 
samples during the treatment of the patient with Csa. (b) serum 
creatinine and egFR (CKd-epi) measured during the treatment of the 
patient with Csa.
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supplementary Material
supplementary Figure 1. Arrow A shows a glomerulus 
with normal capillary loops, regular thickness of mesangial 
matrix and peripheral capillary basement membrane, and flat 
podocytes. Arrow B shows a glomerulus with segmental glom-
erular sclerosis. This glomerulus shows the loss of capillary 
lumen and the adhesion of sclerotic lesions to the Bowman’s 
capsule. No mesangial and endothelial hypercellularity, no acti-
vated podocytes. Chronic unspecific inflammation accompany-
ing with interstitial fibrosis and tubular atrophy (PAS × 200).
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